Drug updated on 11/16/2023
|Injection (intravenous; 600 mg/6 mL)
|Monoclonal antibodies directed against the protective antigen of Bacillus anthracis
|Ongoing and Completed Studies
- Indicated in adult and pediatric patients for treatment of inhalational anthrax due to B. anthracis in combination with appropriate antibacterial drugs and, for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.
Product Monograph / Prescribing Information
|Anthim (obiltoxaximab) Prescribing Information.
|Therapeutics, Inc., Parsippany, NJ
Systematic Reviews / Meta-Analyses
|Assessment report: obiltoxaximab SFL.
Clinical Practice Guidelines
|Virginia Department of Health Anthrax: Guidance for Healthcare Providers Key Medical and Public Health Interventions after Identification of a Suspected Case.
|Virginia Department of Health
|Use of anthrax vaccine in the united states: recommendations of the advisory committee on immunization practices, 2019.
|Morbidity and Mortality Weekly Report- Recommendations and Reports